FDA Approves the new therapy of methadone for bacterial pneumonia
Last Update: 2020-06-19
Search more information of high quality chemicals, good prices and reliable suppliers, visit
The specific pneumonia treatment is hospital acquired / respirator associated bacterial pneumonia (habp / vabp)This is a kind of pneumonia that is easy to get in hospitals and other medical institutionsThe cause of pneumonia involves a variety of different bacteriaAccording to CDC data, habp / vabp is the second most common hospital infection in the United StatesIn serious cases, it can even take the lives of patients< br / > today, zerbaxa, approved for the treatment of this disease, is an antibiotic combination product that includes ceftolozane, a cephalosporin antibiotic, and tazobactam, a β - lactamase inhibitorIt is expected to treat a variety of Gram-negative bacteria that cause habp / vabp< br / > source: MSD < br / > in a phase 3 clinical trial, the researchers recruited 726 patients with habp / vabpStudies have shown that zerbaxa is non inferior to the broad-spectrum antibiotic meropenem, so it can be used as a new therapy for this populationPreviously, the treatment has also been awarded the qualification of qualified infectious disease product (qidp) by the US FDA, as well as the qualification of priority reviewToday it was approved to allow this treatment to come to patients and treat their diseases< br / >In view of the increasing drug resistance of bacteria, new treatments for these infections can meet the needs of patientsWe are also promoting the development of safe and effective new therapies, and bringing more new programs for patients to fight against fatal infections" < br / > reference materials: < br / >  FDA approvesmerck's zebaxa ® (ceftolozane and tazobactam) 3G do for the treatment of results with hospital acquired and vector associated Ba, Retrieved June 3, 2019, from < br / > original title: courier | treatment of bacterial pneumonia, FDA approved the new treatment of MSD today
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to email@example.com
. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.